| 57 | 0 | 35 |
| 下载次数 | 被引频次 | 阅读次数 |
药物相关问题（DRP）是药学监护实践的基石，识别、预防和解决DRPs是药学监护的核心工作任务。DRPs分类系统是药师开展药物治疗管理的重要工具。该综述全面阐述了国内外主流的DRP分类系统，包括PCNE分类系统、ABC分类系统、APS-Doc分类系统、Granada-Ⅱ分类系统、WESTERLUND分类系统、DOCUMENT分类系统、HEPLER-STRAND分类系统及《中国药物相关问题分类系统（V1.0）》，详述了这些DRPs分类系统的各自特点与应用，旨在帮助药师系统把握DRPs的分类和管理方法。该综述对于提升药师的临床决策水平、工作效率及推动药学监护的深入研究，均具有重要意义。
Abstract：Drug-related problems(DRPs) are the cornerstone of pharmaceutical care practice, and the identification, prevention, and resolution of DRPs are the core tasks of pharmaceutical care. DRP classification systems are essential tools for pharmacists to provide medication therapy management services. This article provides a comprehensive review of the commonly used DRP classification systems both at home and abroad, including the Pharmaceutical Care Network Europe(PCNE) classification system, ABC classification system, APS-Doc classification system, Granada-Ⅱ classification system, WESTERLUND classification system, DOCUMENT classification system, HEPLER-STRAND classification system, and the Chinese classification system for drug-related problems(V1.0). The characteristics and applications of these DRPs classification systems are summarized, which helps pharmacists to fully understand the classification and management strategies of DRPs. This is of great significance for improving pharmacists' skills of medication therapy management and work efficiency, as well as for conducting in-depth research on pharmaceutical care practice.
[1]MAO W H,VU H,XIE Z N,et al.Systematic review on irrational use of medicines in China and Vietnam[J].PLoS One,2015,10(3):e0117710.
[2]HOGERZEIL H V.Promoting rational prescribing:an international perspective[J].Br J Clin Pharmacol,1995,39(1):1.
[3]SENDEKIE A K,KASAHUN A E,LIMENH L W,et al.Clinical and economic impact of adverse drug reactions in hospitalised patients:prospective matched nested case-control study in Ethiopia[J].BMJ Open,2023,13(6):e073777.
[4]ANGAMO M T,CHALMERS L,CURTAIN C M,et al.Adversedrug-reaction-related hospitalisations in developed and developing countries:a review of prevalence and contributing factors[J].Drug Saf,2016,39(9):847.
[5]PINTOR-MáRMOL A,BAENA M I,FAJARDO P C,et al.Termsused in patient safety related to medication:a literature review[J].Pharmacoepidemiol Drug Saf,2012,21(8):799.
[6]SHOUQAIR T M,RABBANI S A,SRIDHAR S B,et al.Evaluation of drug-related problems in chronic kidney disease patients[J].Cureus,2022,14(4):e24019.
[7]VENUGOPAL J,SHALINI S,RAJASEKARAN A,et al.Drugrelated problems in cancer patients:a systematic review[J].J Oncol Pharm Pract,2024,30(3):562.
[8]AL-AZAYZIH A,KANAAN R J,ALTAWALBEH S M.Assessment of drug-related problems and health-related quality of life domains in elderly patients with type 2 diabetes mellitus[J].Ther Clin Risk Manag,2023,19:913.
[9]余自成,刘皋林.药物治疗管理服务:药学监护实践中新的机遇[J].中国临床药学杂志,2015,24(5):313.
[10]PCNE Working Group On Drug-Related Problems.The PCNE Classification V9.1[EB/OL].(2020-05-10)[2024-10-25].https://www.pcne.org/upload/files/555 09 PCNE classification V9-1_final.pdf.
[11] MEYBOOM R H,LINDQUIST M,EGBERTS A C.An ABC of drug-related problems[J].Drug Saf,2000,22(6):415.
[12]SCHAEFER M.Discussing basic principles for a coding system of drug-related problems:the case of PI-Doc[J].Pharm World Sci,2002,24(4):120.
[13]BJ?RKMAN I K,SANNER M A,BERNSTEN C B.Comparing4 classification systems for drug-related problems:processes and functions[J].Res Social Adm Pharm,2008,4(4):320.
[14]HEPLER C D,STRAND L M.Opportunities and responsibilities in pharmaceutical care[J].Am J Hosp Pharm,1990,47(3):533.
[15]WESTERLUND T,ALMARSDóTTIR A B,MELANDER A.Drug-related problems and pharmacy interventions in community practice[J].Int J Pharm Pract,1999,7(1):40.
[16]WILLIAMS M,PETERSON G M,TENNI P C,et al.DOCUMENT:a system for classifying drug-related problems in community pharmacy[J].Int J Clin Pharm,2012,34(1):43.
[17]上海市医院协会临床药事管理专业委员会,上海市药学会医院药学专业委员会.《中国药物相关问题分类系统(V1.0)》使用标准[J].中华预防医学杂志,2022,56(8):1042.
[18]STRAND L M,MORLEY P C,CIPOLLE R J,et al.Drug-related problems:their structure and function[J].DICP,1990,24(11):1093.
[19]GARIN N,SOLE N,LUCAS B,et al.Drug related problems in clinical practice:a cross-sectional study on their prevalence,risk factors and associated pharmaceutical interventions[J].Sci Rep,2021,11(1):883.
[20]SELL R,SCHAEFER M.Prevalence and risk factors of drugrelated problems identified in pharmacy-based medication reviews[J].Int J Clin Pharm,2020,42(2):588.
[21]WESTBERG S M,YARBROUGH A,WEINHANDL E D,et al.Drug therapy problem severity following hospitalization and association with 30-day clinical outcomes[J].Ann Pharmacother,2018,52(12):1195.
[22]WATANABE J H,MCINNIS T,HIRSCH J D.Cost of prescription drug-related morbidity and mortality[J].Ann Pharmacother,2018,52(9):829.
[23]ALRUQAYB W S,PRICE M J,PAUDYAL V,et al.Drug-related problems in hospitalised patients with chronic kidney disease:asystematic review[J].Drug Saf,2021,44(10):1041.
[24]NIRIAYO Y L,GEBREGZIABHER T,DEMOZ G T,et al.Drug therapy problems and contributing factors among patients with epilepsy[J].PLoS One,2024,19(3):e0299968.
[25]PLáCIDO A I,HERDEIRO M T,MORGADO M,et al.Drugrelated problems in home-dwelling older adults:a systematic review[J].Clin Ther,2020,42(4):559.
[26]PANEERSELVAM G S,KENNETH L K C,AFTAB R A,et al.Enhancing medication management in hemodialysis patients:exploring the impact of patient-centered pharmacist care and motivational interviewing[J].PLoS One,2024,19(5):e0300499.
[27]SCHINDLER E,RICHLING I,ROSE O.Pharmaceutical Care Network Europe(PCNE)drug-related problem classification version 9.00:German translation and validation[J].Int J Clin Pharm,2021,43(3):726.
[28]KOUBAITY M,LELUBRE M,SANSTERRE G,et al.Adaptation and validation of PCNE drug-related problem classification v6.2 in French-speaking Belgian community pharmacies[J].Int J Clin Pharm,2019,41(1):244.
[29]GRIESE-MAMMEN N,HERSBERGER K E,MES SERLI M,et al.PCNE definition of medication review:reaching agreement[J].Int J Clin Pharm, 2018,40(5):1199.
[30]NI X F,YANG C S,BAI Y M,et al.Drug-related problems of patients in primary health care institutions:a systematic review[J].Front Pharmacol,2021,12:698907.
[31]DA COSTA F A,SILVESTRE L,PERIQUITO C,et al.Drug-related problems identified in a sample of Portuguese institutionalised elderly patients and pharmacists'interventions to improve safety and effectiveness of medicines[J].Drugs Real World Outcomes,2016,3(1):89.
[32]ROSLI M R,WU D B C,NEOH C F,et al.Economic evaluation of home medication review by community pharmacists(HMR-CP)for patients with type 2 diabetes mellitus(T2DM)[J].J Med Econ,2021,24(1):730.
[33]PARK B,BAEK A,KIM Y,et al.Clinical and economic impact of medication reconciliation by designated ward pharmacists in a hospitalist-managed acute medical unit[J].Res Social Adm Pharm,2022,18(4):2683.
[34]LI Q,QU H J,LV D,et al.Drug-related problems among hospitalized patients with COPD in China's mainland[J].Int J Clin Pharm,2019,41(6):1507.
[35]LIU X X,WANG H X,HU Y Y, et al.Drug-related problems identified by clinical pharmacists in nephrology department of a tertiary hospital in China-a single center study[J].Ann Palliat Med,2021,10(8):8701.
[36]李慧馨,蔡俊,张雨昇,等.PCNE分类系统在老年高血压患者药物相关问题中的应用[J].中南药学,2021,19(3)528.
[37]张莎,王婧,祝德秋.引入PCNE分类系统对社区慢病患者进行药学监护的实践探索[J].中南药学,2020,18(6):1051.
[38]张萍,廖赟,吕丹,等.运用PCNE分类体系对癌痛患者麻醉镇痛药物的处方分析[J].中国药师,2018,21(6):1051.
[39]LIU H,ZHONG Y X,ZENG Z H,et al.Drug-related problems in hospitalised Parkinson's disease patients in China[J].Eur J Hosp Pharm,2022,29(6):308.
[40]ROLLEMA C,VAN ROON E N,EKHART C,et al.Adverse drug reactions of intranasal corticosteroids in the Netherlands:ananalysis from the Netherlands pharmacovigilance center[J].Drugs Real World Outcomes,2022,9(3):321.
[41]MUGOSA S,RADOSAVLJEVIC I,SAHMAN M,et al.Risk factors for adverse drug reactions associated with clopidogrel therapy[J].Open Med,2022,17(1):694.
[42]KR?HENBüHL-MELCHER A,SCHLIENGER R,LAMPERT M,et al.Drug-related problems in hospitals:a review of the recent literature[J].Drug Saf,2007,30(5):379.
[43]HOHMANN C,EICKHOFF C,KLOTZ J M,et al.Development of a classification system for drug-related problems in the hospital setting(APS-Doc)and assessment of the inter-rater reliability[J].J Clin Pharm Ther,2012,37(3):276.
[44]LENSSEN R,HEIDENREICH A,SCHULZ J B,et al.Analysis of drug-related problems in three departments of a German University hospital[J].Int J Clin Pharm,2016,38(1):119.
[45]KOVáCOVáB,DURIZOVáA.Drug-related problems identified by pharmacist-led medication review in Slovak hospitalised patients[J].Pharmazie,2016,71(9):548.
[46]JAYAKUMAR A, ABRAHAM A S,KUMAR S, et al.Critical analysis of drug related problems among inpatients in the psychiatry department of a tertiary care teaching hospital:a pharmacist led initiative[J].Clin Epidemiol Glob Health,2021,11:100743.
[47]PRATHEEKSHA N M,VIJAYAN V,PINTO S J,et al.Evaluation of drug related problems among the geriatric inpatients of psychiatry department:a retrospective study[J].Aging Med Healthc,2023,14(1):29.
[48]HOHMANN C,NEUMANN-HAEFELIN T,KLOTZ J M,et al.Drug-related problems in patients with ischemic stroke in hospital[J].Int J Clin Pharm,2012,34(6):828.
[49]SALGADO T M,REYNOLDS T N,FRANKART L M,et al.A key performance indicators redefinition initiative at a school of pharmacy using a modified Delphi consensus technique[J].Pharm Pract,2020,18(4):2120.
[50]MUNRO M G,BALEN A H, CHO S,et al.The FIGO ovulatory disorders classification system[J].Hum Reprod,2022,37(10):2446.
[51]MALDONADO C,FIGLIOLO R,MOUTA A,et al.Implementing pharmacovigilance through pharmaceutical care:a three-month pilot study with patients with systemic lupus erythematosus[J].World J Pharm Pharm Sci,2015,4(7):213.
[52]JAVEDH S,GM R P,BS S,et al.A systematic review on the impact of clinical pharmacist interventions in patients with mentalhealth disorders[J].Clin Schizophr Relat Psychoses,2020,14(3):73.
[53]高妍,任晓倩,戴辉,等.基于Granada-Ⅱ分类法评价临床应用华法林的药物相关问题[J].医药论坛杂志,2022,43(20):12.
[54]王晓玲,李晓慧,梁海,等.基于Granada-Ⅱ分类法对临床应用利伐沙班药物相关问题的评价[J].中华全科医学,2022,20(9):1608.
[55]俞吉,冉烁,王茵,等.基于Granada-Ⅱ分类法对住院患者质子泵抑制剂注射剂药物相关问题的调查分析[J].中国现代应用药学,2021,38(12):1514.
[56]陈慧娟,汪龙,宋佳伟,等.基于Granada-Ⅱ分类法评价住院患儿质子泵抑制药临床使用中的药物相关问题[J].中国药师,2020,23(11):2191.
[57]王双艳,黄德红,徐静逍,等.基于Granada-Ⅱ分类法评价临床应用丹红注射液的药物相关问题[J].中国药事,2022,36(11):1315.
[58]GOPINENI D,MANOHAR REDDY Y V,REDDY MAHESH N,et al.Heralding the drug related problems by using hepler-strand classification in a tertiary care teaching hospital[J].Glob J Pharm Pharm Sci,2020,7(5):146.
[59]SEMCHAROEN K,SUPORNPUN S,NATHISUWAN S, et al.Characteristic of drug-related problems and pharmacists'interventions in a stroke unit in Thailand[J].Int J Clin Pharm,2019,41(4):880.
[60]LIU M Y,LIU J Y,GENG Z H,et al.Evaluation of outcomes of medication therapy management(MTM)services for patients with chronic obstructive pulmonary disease(COPD)[J].Pak J Med Sci,2021,37(7):1832.
[61]黄茜,陈常凤,闫素英,等.依据Beers、STOPP和Strand分类法探讨社区医院老年多重用药患者的用药问题[J].国际老年医学杂志,2023,44(4):419.
[62]WESTERLUND T.Drug-related problems.Identification,characteristics and pharmacy interventions[M].SWE:University of Gothenburg Press,2002:25-26.
[63]KWINT H F,FABER A,GUSSEKLOO J,et al.Effects of medication review on drug-related problems in patients using automated drug-dispensing systems:a pragmatic randomized controlled study[J].Drugs Aging,2011,28(4):305.
[64]WANG X,YANG J,YU X J,et al.Characterization of drug-related problems and associated factors in ambulatory patients in China[J].J Clin Pharm Ther,2020,45(5):1058.
基本信息:
DOI：10.19577/j.1007-4406.2025.12.014
中图分类号:R95
引用信息:
[1]付晓纯,吴婷婷,余自成,等.药物相关问题的主要分类系统及其应用特点[J].中国临床药学杂志,2025,34(12):953-960.DOI:10.19577/j.1007-4406.2025.12.014.